MT-TP and hypertriglyceridemia: MTTP inhibitors have been shown to reduce circulating VLDL and LDL in animal models and human subjects (2, 30, 31) and thus are a valuable addition to the pharmacopoeia for patients with severe hypertriglyceridemia.